126
Results found
-
World Health Day: Working towards universal health coverage in Africa
The Pediatric Praziquantel Consortium marks the World Health Day through its continuous effort to register and launch a child-friendly and new praziquantel formulation for preschool-age children suffering from schistosomiasis. -
From Africa to Asia: Important dialogues for the Pediatric Praziquantel Consortium
Consortium partners have been interacting with the local community in Ivory Coast and with experts from all over the world in Thailand to pave the way for an appropriate access path for the new pediatric drug -
Publication: Relative bioavailability of two novel orally dispersible tablet formulations of praziquantel
In January 2019, researchers from the Pediatric Praziquantel Consortium published the results of two Phase I pharmacokinetic studies in healthy adult volunteers. -
Pediatric Praziquantel Consortium successfully completed Phase II in Ivory Coast
The important milestone of Last Patient Last Visit (LPLV) in the clinical Phase II trial was achieved on November 17, 2018 -
Astellas Global Health Foundation Launches
On 20 November 2018, Astellas Pharma Inc. announced the launch of the Astellas Global Health Foundation (AGHF): a new international philanthropic organization dedicated to improving access to health in underserved global communities. -
From the Program Lead: We have entered the pivotal Phase III stage!
With the Phase II trial showing good results on safety and efficacy for the new orally dispersible praziquantel tablets, the Consortium has entered the pivotal Phase III stage -
Performance Materials at Merck KGaA, Darmstadt, Germany: Key Player towards the success of the Pediatric Praziquantel Program
-
Schistosomiasis in Kenya: an interview with Dr. Maurice R. Odiere
The forthcoming Phase III clinical trial of the Pediatric Praziquantel (PZQ) Consortium Formulation program will be conducted in Kenya, in addition to the Ivory Coast. -
The new SCI elimination strategy
The Schistosomiasis Control Initiative (SCI) has achieved a lot since its foundation in 2002. It has helped to establish programs against parasitic worm infections, including schistosomiasis, in countries where none previously existed, and now supports the delivery of millions of treatments each year. -
The Pediatric Praziquantel Consortium played a leading role at schistosomiasis events in Brazil and Korea
Through a series of meetings and events, the Pediatric Praziquantel Consortium presented the latest achievements of the program and aligned further on next steps. -
Consortium Pediatric Praziquantel presenting at the 67th ASTMH Annual Meeting
Latest clinical data will be presented by the Lead of the Consortium Pediatric Praziquantel program at the 67th ASTMH (American Society of Tropical Medicine & Hygiene) Annual Meeting on October 28-November 1, 2018 (New Orleans, US). -
Publication: Extrapolation of praziquantel pharmacokinetics to a pediatric population
In September 2018, members of the Pediatric Praziquantel Consortium published a paper on the extrapolation of praziquantel pharmacokinetics to a pediatric patient population in the peer-reviewed Journal of Pharmacokinetics and Pharmacodynamics. -
Nature reviews publication: Global overview of schistosomiasis research and control
While considerable progress has been made to control schistosomiasis, challenges remain as there is no vaccine available and the risk for drug resistance is increasing. -
Executive from Merck KGaA, Darmstadt, Germany re-emphasises the importance of addressing the treatment gap of preschoolers infected with schistosomiasis
Initiation of the Phase III development program by the Pediatric Praziquantel Consortium announced at the WHA Schistosomiasis luncheon in Geneva on May 22nd, 2018 -
Renowned African Research Institutes Join Pediatric Praziquantel Consortium
Complementary experience offered by the Kenya Medical Research Institute (KEMRI) and the Université Félix Houphouët-Boigny (UFHB) in conducting clinical trials in sub-Saharan Africa will be instrumental for the success of the Consortium’s phase III program.